Latest News and Press Releases

Bestyrelsen for ALK-Abelló A/S (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler i dag, at den vil indstille Alan Main, tidligere direktør for Consumer Healthcare i Sanofi, som uafhængigt medlem af...

On Wednesday, 11 August 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2021. ALK will host a meeting for analysts and institutional investors that day at...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2021 onsdag den 11. august 2021. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext®, in China via a partnership with leading supplier of adrenaline, Grandpharma.Jext® is expected to be the...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) vil lancere Jext® i Kina via et partnerskab med den førende leverandør af adrenalin, Grandpharma.Jext® forventes at blive den første adrenalinpen på det...

Leading allergy researchers present data from a new, large, ‘real-world evidence’ study of allergy immunotherapy at EAACI Annual Congress in Krakow, PolandStudy assessed long-term outcomes in allergic...

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af...

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No...

Bemærk venligst, at rapporten foreligger udelukkende på engelsk. ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021...

ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021 represented ALK’s best-ever quarter, with revenue exceeding DKK 1...